Bevacizumab (Bev)-based combinations across treatment lines in patients (pts) with metastatic colorectal cancer (mCRC) - interim results from a German non-interventional study (KORALLE) (2017) Eggers E, Uhlig J, Reichert D, Wein A, Schulz H, Beringer A, Arnold D Conference contribution Extension study to the open-label, multi-center, expanded access study of everolimus in patients with advanced neuroendocrine tumors (2017) Doerffel Y, Kullmann F, Lammert F, Quietzsch D, Schöfl C, Schuppert F, Weber M, et al. Conference contribution Combined lanreotide autogel and temozolomide in progressive neuroendocrine tumours: an interim safety analysis of the SONNET study (2017) Hoersch D, Raderer M, Lahner H, Rinke A, Denecke T, Koch A, Raspel A, et al. Conference contribution Overcoming Cost Implications of Mutational Analysis in Patients with Gastrointestinal Stromal Tumors: A Pragmatic Approach (2016) Schöffski P, Wozniak A, Schöffski O, van Eycken L, Debiec-Rychter M Journal article, Original article DasPAQT: Treating Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with Dasatinib - PCR-Monitoring, Adherence, Quality of Life, Therapy Satisfaction (OMC 2014-I; BMS CA180-565) (2016) Tesch H, Pelz H, Janssen J, Hansen R, Fietz T, Anhuf J, Häberle L, et al. Conference contribution DasPAQT: Treating patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with Dasatinib: PCR-Monitoring, adherence, quality of life, therapy satisfaction (OMC 2014-I; BMS CA180-565) - an analysis of the first 150 patients (2016) Tesch H, Pelz H, Janssen J, Hansen R, Fietz T, Anhuf J, Häberle L, et al. Conference contribution Response to 6 cycles of chemotherapy with FOLFIRINOX is predictive of overall survival in patients with locally advanced unresectable pancreatic cancer (2016) Haderlein M, Lubgan D, Lettmaier S, Semrau S, Wolf W, Golcher H, Hohenberger W, Fietkau R Conference contribution LOGIST - A local observational GIST registry: A non-interventional registry to observe patients with gastrointestinal stromal tumors (GIST) after R0/R1 resection - with or without adjuvant therapy with imatinib (CSTI571BDE77) - an interim analysis with 5 (2016) Reichardt P, Quietzsch D, Stuebs P, Cameron S, Gellert K, Wilhelm M, Killing B, et al. Conference contribution Factors Predicting Discordance in HER2 Phenotype between Primary Tumor and Circulating Tumor Cells in Women with Metastatic Breast Cancer (2016) Janni W, Schramm A, Friedl TWP, Schochter E, Huober J, Rack B, Alunni-Fabbroni M, et al. Conference contribution Effective long-term local results and prognostic factors after fractionated stereotactic radiotherapy of 257 intracranial meningeoma (2016) Lubgan D, Rutzner S, Semrau S, Lambrecht U, Roessler K, Buchfelder M, Fietkau R Conference contribution